Newly published research examines association between CKD and CYP24

- Dysregulation of CYP24 linked to chronic kidney disease -

Cytochroma today announced the publication of new data from studies in a preclinical model indicating that chronic kidney disease (CKD) is associated with markedly increased expression of the vitamin D catabolic enzyme, CYP24, which contributes to vitamin D insufficiency and resistance to vitamin D therapy. Parallel analysis of kidney biopsies obtained from CKD patients confirmed abnormal CYP24 expression in human disease as well. The findings were published in Kidney International's advance online publication, and will appear in a forthcoming print edition of Kidney International.

"Our research raises the possibility that aberrantly elevated CYP24 accelerates progression of kidney disease," stated Dr. Martin Petkovich, Cytochroma's Chief Scientific Officer. "Adequate vitamin D hormone supply will normally suppress kidney inflammation and reduce the associated risk of irreversible fibrosis. CYP24, however, inactivates vitamin D hormone and deprives the kidneys of adequate supply. CYP24 also inactivates all currently available vitamin D therapies, making it difficult to treat the hormone deficit in the kidneys."

This newly published research examined CYP24 regulation in relation to vitamin D status in normal rats and in adenine-treated uremic rats, a preclinical model of CKD. As expected, when normal rats were fed a vitamin D deficient diet, CYP24 expression decreased in order to preserve existing vitamin D stores. In contrast, CYP24 expression increased in rats with renal impairment and remained elevated when these rats were fed a vitamin D deficient diet, demonstrating that kidney damage significantly altered the regulation of CYP24 expression. Increased CYP24 expression was separately confirmed in kidney biopsies obtained from CKD patients, suggesting that CYP24 is similarly dysregulated in human renal disease.

These findings indicate that new vitamin D products which resist catabolism by CYP24 and/or minimize CYP24 expression may offer significant advantages over currently available therapies for CKD patients.

Source: CYTOCHROMA

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research explores how antimicrobial exposure affects Parkinson’s disease risk